Current Social/Behavioral Studies

Patient Navigator Research Study
This study's objective is to develop a culturally targeted patient navigation training curriculum aimed at increasing breast, cervical and colorectal cancer screening behaviors in lesbian, gay, bisexual and transgendered (LGBT) persons. Information about barriers to breast, cervical, and colorectal cancer screening faced by LGBT persons will be gathered through 1-hour, face-to-face interviews with LGBT community members who are non-adherent to cancer screening guidelines, as well as with health care providers and facility directors. This information will then be used to adapt and culturally target an existing Health Systems Navigation curriculum which will then be extensively reviewed and field tested prior to implementation. The final, implemented curriculum will help guide patient navigators in the reduction of barriers to appropriate cancer screening and follow-up care in the LGBT community.
 
For more information, please contact Becky at 773-572-8352

MACS (Multicenter AIDS Cohort Study)
The Multicenter AIDS Cohort Study (MACS) is the longest running study of HIV in the world. Funded by the National Institutes of Health (NIH), MACS investigates infection with HIV among men who have sex with men. Since 1983, the Howard Brown Health Center has recruited more than 1,000 individuals to be part of this monumental study. Howard Brown conducts two yearly visits with nearly 300 current participants, during which time the participants receive a physical exam, have blood drawn, and complete an interview with research staff. Numerous sub-studies have been developed from the core MACS, including investigations of cardiovascular disease, renal disease, and neuropsychological functioning as it relates to HIV and Highly Active Antiretroviral Therapy or HAART. 
Enrollment is currently closed. 

For more information regarding MACS, please contact Kate Lindsay at katel@howardbrown.org or (773) 388-8863.

The Smoking Research Project
The Smoking Research Project is currently recruiting HIV+, African American men who have sex with men, ages 21 and over, who currently smoke and want to quit smoking for a one-time focus group with a brief questionnaire.
Participants will be compensated for time and travel.

For more information, please call 773-388-8880.

Text Messaging Study
The Text Messaging study is looking for adult men who have sex with men, ages 25 and over, who are also patients of Howard Brown for a study on the use of technology to improve health. This is a two-visit, three-month long study.

For more information, please contact Nicky Martin at 773-388-8865.

TWISTA (TransWomen Informing Sister TransWomen on AIDS)
TransWomen Informing Sister TransWomen on AIDS (TWISTA) is an HIV intervention program designed to confront some of the many risk factors that make young transgender women of color susceptible to infection with HIV. TWISTA is a peer led 6-session group-based intervention.
Eligibility to participate: self-identified transgender women of color between the ages of 16 and 24.

For more information regarding TWISTA, please contact Nicole Perez at nicolep@howardbrown.org or 773-935-3151 X 281.

Project Q2
Project Q2 is a sixteen month longitudinal study of Lesbian, Gay, Bisexual, Transgender (LGBT) and same-sex attracted youth between the ages of 16 and 20. Project Q2 is designed to learn more about mental health, resiliency, HIV risk and substance use among young members of the LGBT community. Information garnered from Project Q2 will be used to develop improved health and social services for the LGBT youth. 
Recruitment for Project Q2 is now closed.

For more information regarding Project Q2, please contact Steve Garcia at projectq2@psych.uic.edu or 312-996-4208. 

Multi-System Evaluation of Massage Therapy and Relaxation Training on Unmedicated HIV+ Adolescents
The Multi-System Evaluation of Massage Therapy and Relaxation Training on Unmedicated HIV+ Adolescents is designed to determine whether relaxation exercises or massage therapy improve the functioning of the immune system of HIV positive adolescents between the ages of 12 and 24. This project is a collaboration between Children’s Memorial Hospital and Howard Brown Health Center. Participants in this study will be randomly assigned to receive 24 sessions of either massage therapy or relaxation exercises. The intervention sessions are 30 minutes long and take place twice a week for 12 weeks. In addition, there are four 60 minute assessments: one before and after the 12 weeks of massage therapy or relaxation training and one at 3 months and 6 months after the intervention is completed. Recruitment began March 2008
Eligibility to participate: individuals between the ages of 12 and 24 diagnosed with HIV infection with a CD4 count above 200 cells/mL. Additionally, interested individuals must have their primary health care provider’s approval to participate in the study, not be taking (or have a prescription for) medication for HIV infection, not be currently substance dependent, and not have open sores or wounds.

For more information about this Multi-System Evaluation, please contact Kate Sharidan at kates@howardbrown.org or 773-388-1600.

MyPeeps (Male Youth Pursuing Education, Empowerment & Prevention around Sexuality)
MyPeeps is an HIV prevention intervention developed for young men. The MyPeeps intervention was developed by Howard Brown according to the insights of young men who acquired HIV during adolescence. MyPeeps consists of 6 highly interactive group sessions conducted across several weeks. The intervention is supplemented by an informational web component.

For more information about MyPeeps, please contact Marco Hidalgo at MyPeeps@howardbrown.org or 773-572-6985.

C-Talk
C-Talk is designed to develop a tailored, culturally appropriate group-based intervention for a broad population of men who engage in high-risk sex in the context of stimulant use, and who are contemplating or attempting to reduce or stop drug use.  The intervention will function as a relapse-prevention adjunct to treatment, but will also be designed to include persons not in treatment.

For more information regarding C-Talk, please contact Nicole Perez at nicolep@howardbrown.org or 773-388-8872.

Current Clinical Studies

GS US 236-0103 
GS US 236-0103 is a Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Elvitegravir/ Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Ritonavir-Boosted Atazanavir Plus Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.
Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

GS US 216-0114 
GS US 216-0114is a Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9350-boosted Atazanavir Versus Ritonavir-boosted Atazanavir Each Administered with Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 infected, Antiretroviral Treatment-Naïve Adults.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.
Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

GSK EPZ113734
GSK EPZ113734 is a Prospective, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Simplifying from a Regimen of Atazanavir + Ritonavir + Tenofovir/Emtricitabine to Atazanavir + Abacavir/Lamivudine Without Ritonavir for 48 Weeks in Virologically Suppressed, HIV-1 Infected, HLAB* 5701 Negative Subjects.  Participants may receive study medication and lab work at no charge and are compensated for time and travel.
Enrollment is currently open.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

ICE-001
ICE-001 is a Phase 4 Study of the Effect on Immune Reconstitution of a Lopinavir/Ritonavir-Based versus an Efavirenz-Based HAART Regimen in HIV-Infected Subjects.  Participants receive study medication and lab work at no charge and are compensated for time and travel. 
Enrollment is currently open.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Pfizer A4001067
Pfizer A4001067 is an International, Multicenter, Prospective Observational Study of the Safety of Maraviroc used with Optimized Background Therapy in Treatment-Experienced HIV-1 Infected Patients.   Participants will be compensated for time and travel. 
Enrollment is currently open.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Gilead ELV vs RAL (GS 183-0145)
GS 183-0145 is a Multicenter, Randomized, Double-Blind, Double Dummy, Phase 3 Study of the safety and efficacy of Ritonavir-Boosted Elvitegravir (EVG/r) versus Raltegravir (RAL) each administered with a background regimen in HIV-1 Infected, Antiretroviral Treatment-Experienced Adults. The trial evaluates the effectiveness of a new HIV drug in individuals that are failing their current HIV medication regimen. Participants receive study medication and lab work at no charge and are compensated for time and travel.
Enrollment is closed for this study.

For more information or to see if you qualify to participate in GS 183-0145, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Gilead ELV (GS 183-0130)
GS 183-0130 is a Phase 2, Open-Label, Multicenter Study of the Safety of Ritonavir-Boosted GS-9137 (GS-9137/r) Administered in Combination with Other Antiretroviral Agents for the Treatment of  HIV-1 Infected research participants.
Enrollment is closed for this study.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Gilead SWIFT (GS 164-0216)
GS 164-0216 is a Prospective, Randomized, Open-Label Phase IV Study to Evaluate the Rationale of Switching from Fixed-Dose Abacavir (ABC)/Lamivudine (3TC) to Fixed-Dose Tenofovir DF (TDF)/Emtricitabine (FTC) in Virologically Suppressed, HIV 1 Infected Patients Maintained on a Ritonavir-Boosted Protease Inhibitor Containing Antiretroviral Regimen. Participants may receive study medication and lab work at no charge and are compensated for time and travel.
Enrollment is closed for this study.

For more information or to see if you qualify, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Merck HPV Vaccine Study (V501-020)
V501-020 evaluates a new vaccine that may prevent genital and anal warts in men between the ages of 16 and 26 years of age who identify as men who have sex with other men.  
Enrollment is closed for this study.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Since 2007, Howard Brown Health Center has been part of the Adolescent Medicine Trials Network (ATN). As part of the Adolescent Medicine HIV/AIDS Research Network, ATN is the only national study of the emerging HIV epidemic in teens infected through sex or injecting-drug behaviors. The information derived from this network informs the nation’s adolescent-specific HIV/AIDS scientific agenda to improve the prevention of HIV infection and the medical treatment of HIV-positive youth. The primary mission of the ATN is to conduct research, both independently and in collaboration with existing research networks on promising behavioral, microbicidal, prophylactic, therapeutic, and vaccine modalities in HIV-infected and HIV-at-risk adolescents between the ages of 12 and 24.

ATN 061
ATN clinical trial 061 investigates the use of an "oncology" model to treat HIV-positive youth and its effects on immune system preservation and medication adherence. Participants will be randomized to either standard care practices or to early treatment with Atazanavir, Truvada and Norvir. After one year, participants with a HIV viral load less than 100copies/mL and a CD4-Cell count greater than 350cells/mL will be de-intensified to Atazanvir and Norvir. ATN 061 is a three-year study.
Eligibility to participate: individuals between the ages of 18 and 24 who are HIV +, have not been on Highly Active Antiretroviral Treatment (HAART), have a CD4 count greater than 350cells/mL and an HIV viral load less than 100,000 copies/mL.

For more information regarding ATN 061, please contact Julia Brennan RN at jbrennan@childrensmemorial.org or 773-388-8934

ATN 063
ATN clinical trial 063 looks at the effect of taking 50,000 IU of Vitamin D has on bone loss and kidney damage associated with Tenofovir use. Participants will be separated into two arms (tenofovir vs non-tenofovir containing regimens) then randomized to receive placebo or Vitamin D. The intervention period is 12 weeks and includes a total of five visits.
Eligibility to participate: individuals between the ages of 18 and 24 who are HIV + and have been on a stable Highly Active Antiretroviral Treatment (HAART) regiment for the past 90 days.

For more information regarding ATN 063, please contact Julia Brennan RN at jbrennan@childrensmemorial.org or 773-388-8934

ATN 064
ATN clinical trial 064 investigates immune response, tolerability, and behavioral impact of the HPV vaccine in HIV positive women.  Participants will receive an HPV -6, -11,-16, -18, vaccination and will be followed for a period of 48 weeks.  The study includes seven visits.
Eligibility to participate: women between the ages of 16 and 24 who are HIV+ and have not received Highly Active Antiretroviral Treatment (HAART) regiment for at least 6 months prior to study entry or on stable HAART regiment with two HIV-1 RNA plasma viral loads below 400 copies/ml within the 6 months prior to study entry.

For more information regarding ATN 064, please contact Julia Brennan RN at jbrennan@childrensmemorial.org or 773-388-8934

ATN 066B
ATN clinical trial 066B recreates the process and timeline of care-seeking among HIV+ youth, and evaluates technical aspects of identification and recruitment of HIV+ adolescents who have not engaged in care or who have not maintained care.  Participants will be asked to complete a questionnaire on a computer, to assess constructive and dysfunctional social problem-solving, mental and physical health, stigmatization, and substance use.  The study includes one visit.
Eligibility to participate: individuals between the ages of 14 and 24 who are HIV+, diagnosed between six to twelve months prior to study entry, and never initiated HIV related care or dropped out of care for more than twelve months.

For more information regarding ATN 066B, please contact Julia Brennan RN at jbrennan@childrensmemorial.org or 773-388-8934

ATN 071
ATN clinical trial 071 evaluates the impact of early initiation of Highly Active Antiretroviral Treatment (HAART) on preventing neurocognitive decline in HIV-infected adolescents compared to no-treatment and initiation following current Department of Health and Human Services (DHHS) guidelines.  Participants will start HAART at different points and will be evaluated with various psychological measures.  The study includes five visits over the three year period.
Eligibility to participate: individuals between the ages of 18 and 24 who are HIV+, never initiated HAART (except for females on PMTCT for six months), and must commit to three year study period.

For more information regarding ATN 071, please contact Julia Brennan RN at jbrennan@childrensmemorial.org or 773-388-8934

Past Social/Behavioral Studies 

Cancer Screening through Patient Navigation
The Cancer Screening through Patient Navigation study was designed to promote breast and cervical cancer screening among lesbians and bisexual women. Participants were self-identified lesbians or bisexual women aged 21 and over who had not had a pap test or mammogram in the last two years. To encourage breast and cervical cancer screening, Howard Brown developed and piloted an innovative intervention that combined standard education about cancer screening with patient navigation; patients were paired with patient navigator, paraprofessionals who work with individual patients, to help them navigate the health care system. Enrollment is closed and data analysis is underway to determine the effectiveness of patient navigators in convincing women to get screened for cancer. 

For more information, please contact Nicole Perez at nicolep@howardbrown.org or 773-388-8872.

CHIP (Context of HIV Infection Project)
CHIP, was a substudy that ran concurrently with Project 1; participants in Project 1 who were determined to be recently infected with HIV (within 6 months) were filtered into CHIP.  Each HIV-positive individual was matched with three HIV-negative individuals and administered in-depth qualitative interviews regarding sexual behaviors, substance use behaviors, social support systems, psychosocial stressors and stress-coping mechanisms, and beliefs and knowledge of HIV.  Funding from the CDC allowed for recruitment at Howard Brown Health Center, several Chicago Department of Public Health STD Clinics, and Community Outreach Intervention Project (COIP) sites.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Explore
Explore was a Randomized Clinical Trial of the Efficacy of a Behavioral Intervention to Prevent Acquisition of HIV among Men who have Sex with Men. The following is a summary of the Explore results drawn from several papers, including an article from The Lancet.

Results indicate that there were fewer new HIV infections in the intervention group compared with the control group. This difference was not statistically significant, however, and was not at the level of benefit targeted by the research team.

The results suggest that the intervention had a modest benefit in preventing HIV infection and decreasing high-risk behavior among participants compared with standard biannual counseling and testing, and that that benefit occurred early in follow-up (within the first 18 months).

The Explore intervention did affect some important risk behaviors. For example, it significantly reduced the occurrence of unprotected receptive anal intercourse (i.e., being a "bottom") with HIV positive or unknown status partners by 20.5%.

Declines in HIV incidence and sexual risk were seen in both groups (intervention and control) of the study. The full effect of the intervention may have been muted since participants in both groups received considerable attention over the course of the study to maintain involvement and retention. Thus, participation in the control group was not equivalent to "usual care" in which persons would voluntarily seek anonymous counseling and testing.

In summary, the Explore study has made several notable achievements and provided some valuable research lessons:
* There continues to be a high incidence of HIV infection among men who have sex with men (MSM). The HIV incidence rate for Explore was 2.1 percent. During the course of the trial, there were 259 new cases of HIV. The incidence rate of 2.1 percent is higher than anticipated; researchers expected a rate of 1.55 percent when they were designing the study.
* The study observed declines in some high-risk behaviors – that is, the methods by which people contract HIV – in both arms of the study.
* Explore showed that it is possible to do large-scale behavioral intervention studies among MSM.
* There was community participation and interest in the development, implementation and dissemination of results of the study.
* Explore provided lessons about the recruitment of large groups of high-risk MSM. The study recruited 4,295 participants in total. The risk profile of the screened participants is discussed in the Explore baseline papers. A paper detailing the Explore recruitment process is in the works.

The study achieved groundbreaking retention rates for a behavioral study, with a participant retention rate of 87 percent (85 percent in the standard arm and 89 percent in the control arm) over 4 years. A paper discussing the lessons learned regarding retention is in progress.

You can find the latest in Explore results on the study website, www.explorestudy.org.

Life Skills
Life Skills developed and evaluated a multi-dimensional manualized HIV prevention program that fits the unique needs of male-to-female (MTF) transgender young women between the ages of 16 and 24. Lifeskills was a group-based intervention that consisted of 6 sessions over a 3-week period. Ten transgender women were recruited for each cohort, 5 cohorts were held.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Project ICARE (Intervening for Community Awareness, Respect & Empowerment)
Project ICARE examines whether group counseling will reduce sexual and health risk behaviors of African American men who have sex with men. Participants are randomly assigned to either an intervention group or a non-group control arm. Participants in the intervention group are asked to attend approximately 6 visits over approximately 5 months, including a 3 month follow-up session for participants in both the group intervention and control arm. All participants receive a stipend for volunteering their time. HIV-negative participants receive free HIV testing. Project ICARE is a collaborative research study of Howard Brown, the University of Illinois at Chicago, South Side Help Center, the City of Chicago Department of Public Health and the Centers for Disease Control and Prevention. Recruitment for Project ICARE ended in 2009.
Eligibility to participate: HIV positive and negative African American men who have sex with men, aged 18 and over. Men who participated in the Pilot Study for ICARE are not eligible. 

For more information regarding Project ICARE, please contact the Howard Brown Department of Research at 773-388-8880.

Project 1
Project 1 was a multi-site study designed to evaluate the quality of current prevention programs. The results will be used to improve planning and decision-making about HIV prevention. Participants in the study were18 years or older, lived in Chicago, Dallas, or Los Angeles, understood English or Spanish, had been diagnosed as HIV positive within the last six months, and had never taken antiretroviral medication (ARV, anti-AIDS medication).

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Project MIX
Project MIX examined whether group counseling would reduce sexual risk behavior of substance using men who have sex with men (MSM). Participants were both HIV-positive and HIV-negative MSM. Enrollment is closed and data analysis is underway.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Project Q
Project Q was an investigation of HIV risk behaviors among young people between the ages of 16 and 24 who identified as lesbian, gay, bisexual or transgender. Participants were asked to complete a computer- based survey that lasted approximately 1 to 1 1/2 hours. All participation was anonymous.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Project Qi 
Project Qi was designed to identify factors associated with HIV-related risk in a specific subpopulation of vulnerable youth using a sample of Lesbian, Gay, Bisexual, and Transgender (LGBT) individuals between the ages of 14 and 24 and to test the feasibility of using the internet to recruit participants and to collect data via an online survey. Recruitment followed one of three approaches: online outreach through websites frequented by LGBT youth (e.g. myspace, friendster, facebook); advertising on these websites; and referral from participants. Our findings will assist in the creation of much needed HIV prevention programming for vulnerable youth.

For more information about Project Qi, please contact Amy Stauffer at amys@howardbrown.org or 773-935-3151 x280.

Tailored Cancer Screening Study
The Tailored Cancer Screening study developed and tested new ways to motivate men and women to get screened for cancer (breast, cervical, and colon) through tailored messaging.

For more information about the Tailored Cancer Screening Study, please contact Nicole Perez at nicolep@howardbrown.org or 773-388-8872.

TAP (Treatment Advocacy Program)
The Treatment Advocacy Program (TAP) evaluated a behavioral intervention for sexual safety and treatment adherence among 300 men who have sex with men infected with HIV. TAP was designed to help HIV+ men cope with HIV, stay sexually safe, and take their HIV medications regularly. The program consisted of four counseling visits with an HIV+ peer advocate during the first two months, followed by maintenance visits every three months for 18 months. The intervention combined sexual risk reduction, medication adherence, and general coping skills into an integrated, structured package. Participants were randomly assigned to the coping program, or received standard care for 12 months before receiving the coping program. Click here to access a presentation on preliminary findings.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

TRYP (Transgender Research Youth Project)
The TRYP (Trangender Research Youth Project) was a collaboration between Howard Brown Health Center and Children’s Hospital of Los Angeles designed to examine HIV risk behavior among trans feminine youth between the ages of 14 and 24. Participants were asked to complete a quantitative survey lasting approximately 45 minutes. Some participants were asked to return to complete a qualitative interview that lasted from one to two hours.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Past Clinical Studies

Abbott M05-730
Abbott M05-730 was a 48-week clinical study among- HIV positive research participants starting HIV medications for the first time. This study compared dosing and pill types of the various forms of a popular HIV medication.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Abbott M06-802
Abbott M06-802 was a clinical study for HIV+ participants (men and women) in need of an alternative HIV medication regimen.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Abbott KLEAN
The Abbott KLEAN Study enrolled HIV+ patients starting HIV medications for the first time. Patients were randomly assigned to take either Kaletra and Epzicom or Lexiva and Epzicom. Preliminary results show that patients in each group responded similarly to treatment. Of the patients who started with viral loads greater than 100,000 copies/ML, 75% of Lexiva patients and 73% of Kaletra patients became undetectable (<400 copies/ml). As for safety, both regimens were well tolerated. A total of 55 participants withdrew from the study due to a side effect, 7% were in the Lexiva group and 6% were in the Kaletra group. Together, the efficacy and safety data show that Lexiva is non-inferior to Kaletra when used with Epzicom for a first-line regimen.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Abbott STD
Abbott STD  was a study of a new investigational test that detects the presence of Chlamydia and gonorrhea in men and women. The results of this study helped determine if the test is accurate in detecting sexually transmitted diseases. Participants were men and women who had been sexually active in the last 6 months, were 18 years of age or older, and had not taken antimicrobial therapy for either sexually transmitted diseases in the last 21 days.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Boehringer Ingelheim 1182.116
Boehringer Ingelheim 1182.116 was a clinical study for HIV+ participants (men and women) in need of an alternative HIV medication regimen. The study involved two visits over 45 days. Participants received lab tests and completed a brief questionnaire.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

CDC Rapid HIV Testing Study
The CDC Rapid HIV Testing Study evaluated and compared four types of HIV tests in men and women between the ages of 18 and 55 known to be HIV positive.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

ePEP
Post-Exposure Prophylaxis (PEP) has been shown to be effective in preventing HIV when used by patients after an event that may have put them at risk for contracting this disease. ePEP was a clinical trial evaluating the feasibility of prescribing take-home PEP medications. Click here to access a presentation on findings.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Graceway Genital Warts Treatment (GW01-0805)
GW01-0805 was a Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy and Safety Study of Imiquimod Creams in the Treatment of External Genital Warts.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Gilead Integrase Inhibitor (GS 183-0105)
GS 183-0105 compared a new class of HIV medications, Integrase Inhibitors, with the other FDA approved antiretroviral medication classes.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

GS US 236-0102
GS US 236-0102 is a Phase 3, Randomized, Double-Blind, Study to Evaluate the Safety and Efficacy of Elvitegravir/ Emtricitabine/Tenofovir Disoproxil Fumarate/GS-9350 Versus Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in HIV-1 Infected, Antiretroviral Treatment-Naive Adults.  Participants may receive study medication and lab work at no charge and are compensated for time and travel. 
Enrollment is closed for this study.

For more information, please contact Christina DiLauro Abaya at christinaa@howardbrown.org or 773-388-8792.

Merck HIV Vaccine Study (V520-016)
V520-016 was a Phase-I clinical trial evaluating a new vaccine that may prevent HIV. Participants were 18 years or older, male or female, and HIV-negative.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Merck HIV Vaccine Phase IIa (V520-020)
V520-020 was a one year, Phase IIa study evaluating at the safety and efficacy of a new vaccine that may prevent HIV.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Pfizer A4001060
A4001060 was a clinical trial testing the Short-Term response of Viral Load to Maraviroc Added to a Failing Regimen, with Tropism Assay, in HIV-1 infected patients.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Pfizer Expanded Access
Pfizer Expanded Access was a clinical study for HIV+ participants (men and women) in need of an alternative HIV medication regimen they were currently taking.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.

Roche Gemini
Gemini was a 48-week clinical study for HIV positive subjects who had never before taken HIV medications and were interested in beginning an HIV medication regimen.

For more information, please contact the Howard Brown Department of Research at 773-388-8880.